Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study

Table 3 Comparison of secondary endpoints among different regimens

Therapeutic regimen	OS (m)	95% CI				Extracranial ORR	P value
Group A	27.9	22.6–33.2	0.577	28.6% (21/75)	0.339	48.6% (35/74)	0.139
Group B	24.4	18.5–30.2	0.577	36.6% (15/41)	0.339	62.2% (23/37)	0.139
Group C	N/A	-	0.458	66.7% (6/9)	1.000	71.4% (5/7)	1.000
Group D	N/A	-	0.458	64.3% (9/14)	1.000	80.0% (8/10)	1.000
Group A + B	25.9	22.0-29.9	0.043	31.0% (36/116)	0.002	52.3% (58/111)	0.108
Group C + D	N/A	-	0.043	65.2% (15/23)	0.002	76.5% (13/17)	0.108

Note: Group A: 1st generation EGFR-TKIs monotherapy; Group B: 1st generation EGFR-TKIs + pemetrexed plus cisplatin/carboplatin chemotherapy; Group C: 1st generation EGFR-TKIs + bevacizumab; Group D: 1st generation EGFR-TKIs + pemetrexed plus cisplatin/carboplatin chemotherapy + bevacizumab
Abbreviations: m, month; N/A, not reached; ORR, overall remission rate; OS, overall survival; TKI, tyrosine kinase inhibitor

ISSN: 1471-2407